No abstract available
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Angiogenesis Inhibitors / pharmacology
-
Angiogenesis Inhibitors / therapeutic use
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / secondary
-
Disease-Free Survival
-
Everolimus
-
Humans
-
Indazoles
-
Indoles / pharmacology
-
Indoles / therapeutic use
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / pathology
-
Niacinamide / analogs & derivatives
-
Niacinamide / pharmacology
-
Niacinamide / therapeutic use
-
Phenylurea Compounds / pharmacology
-
Phenylurea Compounds / therapeutic use
-
Pyrimidines / pharmacology
-
Pyrimidines / therapeutic use
-
Pyrroles / pharmacology
-
Pyrroles / therapeutic use
-
Randomized Controlled Trials as Topic
-
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors*
-
Sirolimus / administration & dosage
-
Sirolimus / analogs & derivatives
-
Sorafenib
-
Sulfonamides / pharmacology
-
Sulfonamides / therapeutic use
-
Sunitinib
-
TOR Serine-Threonine Kinases / antagonists & inhibitors*
-
Treatment Outcome
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal, Humanized
-
Indazoles
-
Indoles
-
Phenylurea Compounds
-
Pyrimidines
-
Pyrroles
-
Sulfonamides
-
Niacinamide
-
Bevacizumab
-
temsirolimus
-
pazopanib
-
Everolimus
-
Sorafenib
-
MTOR protein, human
-
Receptors, Vascular Endothelial Growth Factor
-
TOR Serine-Threonine Kinases
-
Sunitinib
-
Sirolimus